LAKE FOREST, Ill., Feb. 9, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE:
HSP), the world's leading provider of injectable drugs and infusion
technologies, and a global leader in biosimilars, today announced
that, as a result of its pending merger with Pfizer Inc., it will
not be holding its previously scheduled conference call to discuss
fourth-quarter and full-year 2014 results.
The company will release its fourth-quarter and full-year 2014
results as planned on Feb. 12, 2015,
and intends to file its Annual Report on Form 10-K for the fiscal
year ended Dec. 31, 2014 with the
U.S. Securities and Exchange Commission (SEC), on the same day. As
is the company's standard practice, both documents will be
accessible in the Investor Relations section of Hospira's website
at www.hospirainvestor.com.
About Hospira
Hospira, Inc. is the world's
leading provider of injectable drugs and infusion technologies, and
a global leader in biosimilars. Through its broad, integrated
portfolio, Hospira is uniquely positioned to Advance
Wellness™ by improving patient and caregiver safety while reducing
healthcare costs. The company is headquartered in Lake Forest,
Ill. Learn more at www.hospira.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hospira-cancels-previously-scheduled-conference-call-to-discuss-fourth-quarter-and-full-year-2014-results-300033218.html
SOURCE Hospira, Inc.